Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hepatocellular Carcinoma

Hepatocellular Carcinoma

Part of Cancer

Subtypes of Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma 7 Liver tumors 1

63 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatocellular Carcinoma

159 trials tracked for Hepatocellular Carcinoma: 31 in phase 3 or 4 and 15 with published results. The most-cited published study has 3655 citations.

159Trials tracked
31Phase 3 & 4
0Recruiting
15With published results
Phase distribution
Phase 4 6 Phase 3 25 Phase 2 83 Phase 1 12 Other / NA 33
  1. Phase 3 Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma Completed · 3,655 cited
  2. Phase 3 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Completed · 1,808 cited
  3. Phase 3 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Completed · 1,599 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Completed · 1,087 cited
  5. Phase 3 Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) Completed · 418 cited
  6. Phase 3 Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy Completed · 349 cited
Show 44 more trials
  1. Phase 4 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy Completed · 258 cited
  2. Phase 3 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) Completed · 252 cited
  3. Phase 3 Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) Completed · 184 cited
  4. Phase 3 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Completed · 84 cited
  5. Phase 3 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Completed · 84 cited
  6. Phase 3 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Completed · 66 cited
  7. Phase 3 Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma Completed · 61 cited
  8. Phase 3 Contrast-enhanced Ultrasound Evaluation of Chemoembolization Completed · 23 cited
  9. Phase 3 A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista Completed · 18 cited
  10. Phase 4 Hepatic Xenetix-CT Perfusion Completed
  11. Phase 4 Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients Completed
  12. Phase 4 Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE Completed
  13. Phase 4 SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Completed
  14. Phase 4 Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) Completed
  15. Phase 3 Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) Completed
  16. Phase 3 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed
  17. Phase 3 Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) Completed
  18. Phase 3 A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  19. Phase 3 Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients Completed
  20. Phase 3 Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) Completed
  21. Phase 3 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma Completed
  22. Phase 3 A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  23. Phase 3 Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) Completed
  24. Phase 3 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib Completed
  25. Phase 3 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) Completed
  26. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  27. Phase 2 A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). Completed
  28. Phase 2 Low Dose ICG for Biliary Tract and Tumor Imaging Completed
  29. Phase 2 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib Completed
  30. Phase 2 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma Completed
  31. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  32. Phase 2 Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Completed
  33. Phase 2 Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant Completed
  34. Phase 2 Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors Completed
  35. Phase 2 Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma Completed
  36. Phase 2 A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer Completed
  37. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  38. Phase 2 Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis Completed
  39. Phase 2 Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma Completed
  40. Phase 2 A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients Completed
  41. Phase 2 Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Completed
  42. Phase 2 E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Completed
  43. Phase 2 Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery Completed
  44. Phase 2 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed

Showing the 50 most-cited and recently-updated of 159 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Radiology & Imaging Cohort
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
Frontiers Apr 23, 2026
Expert consensus guideline on TACE for unresectable HCC in Vietnam
Oncology Guideline
Expert consensus guideline on TACE for unresectable HCC in Vietnam Vietnam Unveils New Rules for Liver Cancer Treatment
This expert consensus guideline addresses transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma in …
Vietnam’s medical leaders have created a clear plan to improve liver cancer care.
Frontiers Apr 23, 2026
Integrative review of Epimedium flavonoids in hepatitis and cirrhosis shows preclinical promise but lacks clinical validation
Gastroenterology Sys. Review
Integrative review of Epimedium flavonoids in hepatitis and cirrhosis shows preclinical promise but lacks clinical validation Ancient Herb Shows New Promise for Liver Scarring and Hepatitis
This integrative review synthesizes data from 33 high-impact studies regarding Epimedium species and its bioactive flavonoids, icariin and i…
This research suggests a traditional herb may offer a new way to protect the liver, but more work is needed to prove it’s safe and effective…
Frontiers Apr 22, 2026
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma
Allergy & Immunology Cohort
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma New Liver Cancer Combo Makes Surgery Possible for More Patients
This prospective pilot study enrolled 15 patients with Barcelona Clinic Liver Cancer stage B or C unresectable hepatocellular carcinoma.
This new treatment plan turns advanced liver cancer into operable disease for many patients.
Frontiers Apr 22, 2026
Huaier granules combined with conventional therapy may improve survival in hepatocellular carcinoma
Drug Pipeline RCT
Huaier granules combined with conventional therapy may improve survival in hepatocellular carcinoma Does adding Huaier granules help liver cancer patients live longer when combined with standard treatment?
This systematic review of 4,832 patients found that Huaier granules combined with conventional cancer therapy was associated with improved o…
Adding Huaier granules to standard liver cancer treatment helped patients live longer and slowed disease growth compared to therapy alone.
Frontiers Apr 19, 2026
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Oncology RCT
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Apr 16, 2026
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
Oncology Meta-analysis
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts Do rare gene changes linked to liver disease also raise your risk for cancer and scarring?
This meta-analysis reviews data from the Million Veteran Program, UK Biobank, and clinical cohorts to assess rare APOB variant carriage in p…
Rare gene changes linked to fatty liver disease also raise your risk for liver cancer and severe scarring, according to new findings.
Apr 16, 2026
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
Allergy & Immunology Sys. Review
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients Why Liver Cancer Stops Responding to Immunotherapy — and What Could Change That
This systematic review evaluated drug resistance mechanisms and strategies to overcome resistance in patients with hepatocellular carcinoma …
Understanding why liver cancer learns to dodge the immune system's attack is the first step toward treatments that can keep working long-ter…
Frontiers Apr 16, 2026
Meta-analysis of minimally invasive vs open hepatectomy in patients with obesity and liver tumors
Orthopedics & Sports Medicine Meta-analysis
Meta-analysis of minimally invasive vs open hepatectomy in patients with obesity and liver tumors Less Pain, Less Blood: Surgery for Obese Liver Patients
This systematic review and meta-analysis evaluated minimally invasive hepatectomy (MIH) versus open hepatectomy (OH) in 1,713 patients with …
Minimally invasive liver surgery for obese patients causes less pain and blood loss than traditional open surgery, offering a safer recovery…
Frontiers Apr 16, 2026
Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies
Allergy & Immunology Sys. Review
Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies Review suggests metabolic switch concept may guide future liver cancer treatments
This mini-review examines the role of ACSL4 as a metabolic switch rather than a static oncogenic factor in hepatocellular carcinoma.
Viewing a liver cancer protein as a metabolic switch could guide new therapies that boost a specific cell death process to fight tumors.
Frontiers Apr 15, 2026
Review of bile acid homeostasis regulation in liver disease and cancer
Nutrition & Obesity Medicine Sys. Review
Review of bile acid homeostasis regulation in liver disease and cancer Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…
Frontiers Apr 15, 2026
Immune Checkpoint Inhibitors Improve Survival and Response Rates in Patients with Hepatocellular Carcinoma Compared to Standard Therapy
Gastroenterology Meta-analysis
Immune Checkpoint Inhibitors Improve Survival and Response Rates in Patients with Hepatocellular Carcinoma Compared to Standard Therapy New Drug Gives Liver Cancer Patients More Time
This systematic review and meta-analysis evaluated immune checkpoint inhibitors (ICIs) versus standard therapy or placebo in patients with h…
A new drug helps the immune system fight liver cancer, giving patients more time and better survival rates compared to standard treatments.
Apr 14, 2026

Questions about Hepatocellular Carcinoma

Are there differences in how hepatocellular carcinoma develops based on my liver fibrosis stage?

Yes, advanced liver fibrosis (stage F3-F4) significantly increases the risk of developing hepatocellular carcinoma compared to no or mild fibrosis, with higher cumulative incidence over time.

Full answer →
What gaps exist between lab findings and real-world treatment for hepatocellular carcinoma?

Lab findings often don't translate to real-world HCC care due to tumor heterogeneity, racial disparities, and lack of validated biomarkers for routine use.

Full answer →
Do Black patients have worse survival rates after a liver transplant for hepatocellular carcinoma?

Yes, Black patients have worse survival after liver transplant for hepatocellular carcinoma, with a 27% higher risk of death compared to White patients.

Full answer →
Does having advanced liver scarring increase my risk of developing hepatocellular carcinoma?

Yes, advanced liver scarring (fibrosis/cirrhosis) significantly raises your risk of developing hepatocellular carcinoma, especially in MASLD patients.

Full answer →